Zibar Karin, Ćuća Jadranka Knežević, Blaslov Kristina, Bulum Tomislav, Smirčić-Duvnjak Lea
Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia
Department of Clinical Chemistry and Laboratory Medicine, Merkur University Hospital, Zagreb, Croatia.
Ann Clin Biochem. 2015 Mar;52(Pt 2):220-5. doi: 10.1177/0004563214544709. Epub 2014 Jul 8.
The role of glucagon-like peptide-1 (GLP-1) has become a new scientific interest in the field of pathophysiology of type 1 diabetes mellitus (T1DM), but the results of the published studies were contradictory. The aim of our study was therefore to measure fasting and postprandial GLP-1 concentrations in T1DM patients and in healthy controls and to examine the difference in those concentrations between the two groups of subjects.
The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20-59), with disease duration 22 years (3-45), and 10 healthy controls, median age 30 years (27-47). Fasting and postprandial total and active GLP-1 concentrations were measured by ELISA (ALPCO, USA). The data were statistically analysed by SPSS, and significance level was accepted at P < 0.05.
Both fasting total and active GLP-1 concentrations were significantly lower in T1DM patients (total 0.4 pmol/L, 0-6.4 and active 0.2 pmol/L, 0-1.9) compared with healthy controls (total 3.23 pmol/L, 0.2-5.5 and active 0.8 pmol/L, 0.2-3.6), P = 0.008 for total GLP-1 and P = 0.001 for active GLP-1. After adjustment for age, sex and body mass index, binary logistic regression showed that both fasting total and active GLP-1 remained significantly independently lower in T1DM patients (total GLP-1: OR 2.43, 95% CI 1.203-4.909 and active GLP-1: OR 8.73, 95% CI 1.472-51.787).
T1DM patients had independently lower total and active GLP-1 fasting concentrations in comparison with healthy people, which supports the potential therapeutic role of incretin therapy, along with insulin therapy, in T1DM patients.
胰高血糖素样肽-1（GLP-1）的作用已成为1型糖尿病（T1DM）病理生理学领域新的科研热点，但已发表研究的结果相互矛盾。因此，我们研究的目的是测定T1DM患者和健康对照者空腹及餐后的GLP-1浓度，并检验两组受试者之间这些浓度的差异。
这项横断面研究纳入了30例C肽阴性的T1DM患者，中位年龄37岁（20 - 59岁），病程22年（3 - 45年），以及10例健康对照者，中位年龄30岁（27 - 47岁）。采用酶联免疫吸附测定法（ELISA，美国ALPCO公司）测定空腹及餐后总的和活性GLP-1浓度。数据用SPSS进行统计学分析，显著性水平设定为P < 0.05。
与健康对照者（总的3.23 pmol/L，0.2 - 5.5；活性的0.8 pmol/L，0.2 - 3.6）相比，T1DM患者空腹时总的和活性GLP-1浓度均显著降低（总的0.4 pmol/L，0 - 6.4；活性的0.2 pmol/L，0 - 1.9），总的GLP-1的P = 0.008，活性GLP-1的P = 0.001。在对年龄、性别和体重指数进行校正后，二元逻辑回归显示，T1DM患者空腹时总的和活性GLP-1仍然显著独立降低（总的GLP-1：比值比2.43，95%置信区间1.203 - 4.909；活性GLP-1：比值比8.73，95%置信区间1.472 - 51.787）。
与健康人相比，T1DM患者空腹时总的和活性GLP-1浓度独立降低，这支持了肠促胰岛素疗法联合胰岛素疗法在T1DM患者中的潜在治疗作用。
